Kidney transplantation: The evolving challenges

American Journal of the Medical Sciences

Volumn 328, Issue 3, 2004, Pages 156-161

  Zhang, Rubin ^a   Kumar, Prem ^a   Ramcharan, T ^a   Reisin, Efrain ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

Author keywords

Allograft survival; Cloning; Immunosuppressive drugs; Kidney transplantation; Xenotransplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

BIOENGINEERING; CARDIOVASCULAR DISEASE; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY DISEASE; CLONING; DRUG MECHANISM; EMBRYO CELL; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE AVAILABILITY; HUMAN; HUMAN EMBRYONIC STEM CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LONGEVITY; MORTALITY; ORGAN DONOR; ORGAN PRESERVATION; ORGAN SUPPLY; QUALITY OF LIFE; REVIEW; STEM CELL; XENOTRANSPLANTATION;

EID: 4644322795     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200409000-00004     Document Type: Review

References (62)

1. Murray JE, Merrill JP, Harrison JH, et al. Kidney transplantation between seven pairs of identical twins. Ann Surg 1958;148:343-59.
2. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:606-12.
3. United States Renal Data System: Atlas of ESRD in the United States. Am J Kidney Dis 2001;4:S117-34.
4. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002;73:1923-8.
5. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long term outcomes after renal transplantation. N Engl J Med 2002;346:580-90.
6. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994;331:365-76.
7. Cecka JM. The UNOS renal transplant registry. Clin Transplant 2001:1-18.
8. Cascalho M, Platt JL. Xenotransplantation and other means of organ replacement. Nat Rev Immunol 2001;1:154-60.
9. Hammerman MR. Xenotransplantation of developing kidneys. Am J Physiol Renal Physiol 2002;283:F601-6.
10. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30.
11. Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end stage renal disease: trends over time for transplant recipients and wait-listed patients. Am J Soc Nephrol 2001;12:1293-6.
12. Rabbat CG, Thorpe KE, Russell JD, et al. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000;11:917-22.
13. Ojo AO, Hanson JA, Meier-Kriesche HU, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001;12:589-97.
14. Weber M, Dindo D, Demartines N, et al. Kidney transplantation from donors without a heartbeat. N Engl J Med 2002;347:248-55.
15. Ojo AO, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation. Transplantation 1998;66:1651.
16. Glanton CW, Kao TC, Cruess D, et al. Impart of renal transplantation on survival in end stage renal disease patients with elevated body mass index. Kidney Int 2003;63:647-53.
17. Kasiske BL. Long-term posttransplantation management and complications. In Danovitch GH. Handbook of Kidney Transplantation, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001, pp 182-220.
18. Goodman WG, Danovitch GM. Options for patients with ESRD. In Danovitch GH. Handbook of Kidney Transplantation, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p 1-16.
19. Whiting JF, Zavala EY, Alexander JW, et al. The cost-effectiveness of transplantation with expanded donor kidneys. Transplant Proc 1999;31:1320-1.
20. Denton MD, Magee CM, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999;353:1083-91.
21. Formica RN, Friedman AL, Lorber MI. Evolving role of sirolimus immunosuppression after organ transplantation. Curr Opin Organ Transplant 2002;7:353-8.
22. Lin J, Valeri AM, Markowitz GS, et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002;73:783-8.
23. Nankivell BJ, Borrows RJ, Fung C, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33.
24. Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003;349:2288-90.
25. Prommool S, Jhangri GS, Cockfield SM, et al. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000;11:565-73.
26. Nankivell BJ, Borrows RJ, Fung C, et al. The natura history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33.
27. Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and renal survival. JAMA 2000;283:633-8.
28. Zhang R, Boudreaux P, Frey F, et al. Hypertension after kidney transplantation: impact, pathogenesis and therapy. Am J Med Sci 2003;325:202-8.
29. Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephropathy. Transplantation 2001;71:SS42-51.
30. Abbott KC, Bucci JR, Cruess D, et al. Graft loss and acute coronary syndromes after renal transplantation in the United States. J Am Soc Nephrol 2002;13:2560-9.
31. Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al. The risk of cardiovascular disease associated with protein uria in renal transplant patients. Transplantation 2002;73:1345-8.
32. Rigatto C, Parfrey P, Foley R, et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes and relationship with ischemic heart disease. J Am Soc Nephrol 2002;13:1084-90.
33. Cosio FG, Pesavento TE, Pelletier RP, et al. Patient survival after kidney transplantation: the effects of statins. Am J Kidney Dis 2002;40:638-43.
34. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002;13:1365-73.
35. Oberbauer R, Kreis H, Johnson R, et al. Long-term sirolimus improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2 year results of the rapamine maintenance regiment study. Transplantation 2003;76:364-70.
36. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus vs. cyclosporine. Transplantation 2002;74:1070-6.
37. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69:2405-9.
38. Stigant CE, Cohen J, Vivera M, et al. ACE inhibitors and angiotensin 2 antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kid Dis 2000;35:58-63.
39. Omoto K, Tanabe K, Tokumoto T, et al. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 2003;76:1170-4.
40. Ersoy A, Dilek K, Usta M, et al. Angiotensin-2 receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients. Clin Transplant 2002;16:202-5.
41. Suwelack B, Gerhardt U, Hausberg M, et al. Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation. Am J Cardiol 2000;86:583-5.
42. Klingbeil AU, Muller HJ, Delles C, et al. Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. Am J Hypertens 2000;13:1295-300.
43. Zhang R, Crump J, Reisin E. Regression of left ventricular hypertrophy is a key goal of hypertension management. Curr Hypertens Rep 2003;5:301-8.
44. Weir MR, Ward MT, Blahut SA, et al. Long term impact of discontinued or deduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001;59:1567-63.
45. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57:307-13.
46. Alfrey EJ, Lerner SM, Lu AD. The dual kidney transplant registry. Clin Transpl 2001:107-11.
47. Velidedeoglu E, William N, Brayman KL, et al. Comparison of open, laparoscopic, and hand-assisted approaches to live-donor nephrectomy. Transplantation 2002;74:169-72.
48. Horgan S, Vanuno D, Sileri P, et al. Robotic-assisted laparoscopic donor nephrectomy for kidney transplantation. Transplantation 2002;73:1474-9.
49. Reemtsma K, McCracken BH, Schlegel JU, et al. Renal heterotransplantation in man. Ann Surg 1964;160:384-410.
50. Soin B, Friend PJ. Renal xenotransplantation. In: Morris PJ. Kidney Transplantation: Principles and Practice, 5th ed. Philadelphia: WB Saunders; 2001, p. 745.
51. Rogers SA, Talcott M, Hammerman MR. Transplantation of pig metanephroi. ASAIO J 2003;49:48-52.
52. Parker W, Bruno D, Holzknecht ZE, et al. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994;153:3791-803.
53. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from human injury. Nat Med 1995;1:423-7.
54. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994;57:363-70.
55. Sablinski T, Latinne D, Gianello P, et al. Xenotransplantation of pig kidneys to nonhuman primates: development of the model. Xenotransplantation 1995;2:264.
56. Kroshus TJ, Rollins SA, Dalmasso AP, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995;60:1194-202.
57. Dai Y, Vaught TD, Boone J, et al. Targeted disruption of the alpha 1,3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 2002;20:251-5.
58. Lai L, Kolber SD, Park KW, et al. Production of alpha-1, 3-galactotransferase knockout pigs by nuclear transfer cloning. Science 2002;295:1089-92.
59. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-7.
60. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
61. Langone AJ, Helderman JH. Disparity between solid-organ supply and demand. N Engl J Med 2003;349:704-6.
62. United network for organ sharing (UNOS) and the organ procurement and transplantation network (OPTN) data. Available at: http://www.unos.org/data/ and http://www.optn.org/data/. Accessed May 7, 2004.